Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224050 · ClinicalTrials.gov registry record · Phase 2
Heart Rate Variability Biofeedback for Smoking Cessation Treatment
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT05224050 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 28 participants.
The verdict
NCT05224050, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of the study is to conduct an open trial examining the feasibility and acceptability of an adapted heart rate variability biofeedback and smoking cessation treatment that was using a primarily virtual remote intervention.
Interventions
- DRUG Nicotine patch
- BEHAVIORAL Cognitive-Behavioral Smoking Cessation
- BIOLOGICAL Heart Rate Variability Biofeedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224050
The ClinicalTrials.gov registry entry for NCT05224050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nicotine patch is the first listed.
NCT05224050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05224050 about?
NCT05224050 is a clinical study titled "Heart Rate Variability Biofeedback for Smoking Cessation Treatment". The purpose of the study is to conduct an open trial examining the feasibility and acceptability of an adapted heart rate variability biofeedback and smoking cessation treatment that was using a primarily virtual remote intervention.
What is the current status of trial NCT05224050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-11-29. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT05224050?
The interventions under investigation include: Nicotine patch (DRUG), Cognitive-Behavioral Smoking Cessation (BEHAVIORAL), Heart Rate Variability Biofeedback (BIOLOGICAL).
Who is sponsoring clinical trial NCT05224050?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.